Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | BRS3 | P32247 | 2/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132531 | 0.87 | HSD11B1 (0.37) | PDE10AKCNH2FAAHGABRA1GABRG2 | |
| SCHEMBL4729458 | 0.82 | TRPV4 (0.37) | PDE10AHSD11B1PTGS2TRPV4APLNR | |
| SCHEMBL12001529 | 0.82 | KCNH2 (0.35) | PDE10AKCNH2FAAHGABRA1GABRG2 | |
| SCHEMBL29649716 | 0.80 | TRPV4 (0.40) | PDE10AKCNH2FAAHHSD11B1PTGS2 | |
| SCHEMBL17586504 | 0.80 | TRPV4 (0.40) | PDE10AKCNH2FAAHHSD11B1PTGS2 | |
| SCHEMBL11971234 | 0.79 | MAP3K14 (0.34) | PDE10AKCNH2GABRA1GABRG2GABRB3 | |
| SCHEMBL18635781 | 0.78 | TRPV4 (0.34) | PDE10AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL23262834 | 0.78 | GRM5 (0.35) | PDE10AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL18463843 | 0.78 | TRPV4 (0.34) | PDE10AGABRA5HSD11B1PTGS2TRPV4 | |
| SCHEMBL16019424 | 0.78 | TRPV4 (0.34) | PDE10AGABRA5HSD11B1PTGS2BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771738-B2 | Endoparasitic depsipeptides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2300422-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2014-11-05 | — | — | EP | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-8691804-B2 | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-04-08 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | PDE10A 3272/4885KCNH2 459/4885FAAH 534/4885 |
| US-11771738-B2 | Endoparasitic depsipeptides | VIP, PREP, VIPR1 | PDE10A 1036/4885KCNH2 3221/4885FAAH 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.